Cholesterol Conversations cover art

Cholesterol Conversations

Cholesterol Conversations

By: North American Thrombosis Forum
Listen for free

About this listen

 Statin therapy is the first-line pharmacologic treatment for lowering low-density lipoprotein cholesterol (LDL-C) and reducing atherosclerotic cardiovascular disease (ASCVD) risk. However, evidence-based and guideline-recommended therapies continue to be underutilized — even among the highest risk patients. More education is needed to address gaps in ASCVD care, particularly among patients who cannot reach their LDL-C goals with statin therapy alone. NATF is pleased to launch Cholesterol Conversations, a limited-series podcast discussing the latest guidance on ASCVD management and available treatment options for optimal LDL-C lowering. New data on the efficacy of novel agents and combination therapy is also highlighted.2023 Hygiene & Healthy Living Physical Illness & Disease
Episodes
  • Mastering LDL Management in 2025

    Mastering LDL Management in 2025
    Mar 30 2025
    In this episode of Cholesterol Conversations, host Dr. Heather Johnson, Director of Preventive Cardiology for Women's Services at the Christine E. Lynn Women’s Health & Wellness Institute of Baptist Health South Florida, sits down with Dr. Viet T. Le, Associate Professor of Research and Co-Director of the Preventive Cardiology Clinic at Intermountain Medical Center in Utah. Together, they explore the latest advancements in LDL cholesterol management and discuss how clinicians can optimize risk assessment, treatment strategies, and patient adherence to improve cardiovascular outcomes. From discussing the new AHA PREVENT calculator to strategies for overcoming statin intolerance and emerging lipid-lowering therapies, this podcast provides practical insights into treating and preventing cardiovascular disease in 2025 – in just 30 minutes! 🎧 Listen Now to stay ahead in lipid management and help patients achieve better heart health. This activity has been approved for AMA PRA Category 1 Credit(s)™. After listening to the podcast discussion, go to Boston University Chobanian & Avedisian School of Medicine’s website: Cholesterol Conversations: Mastering LDL Management in 2025 | Chobanian & Avedisian School of Medicine/CCE. Scroll down for more information about CME/CPE credits. 💡 For more educational content on LDL cholesterol management, visit: Vasculearn Network Podcast Chapters: 1. Introduction & Overview (00:06 - 01:18) 2. Why is LDL Important? (01:18 - 03:47) 3. Risk Assessment & Screening Tools (03:47 - 08:39) 4. Special Risk Considerations (08:39 - 10:55) 5. Lipoprotein(a) & Additional Biomarkers (10:55 - 12:05) 6. Treatment Options: Statins & Beyond (12:05 - 17:24) 7. Overcoming Statin Intolerance (17:24 - 21:37) 8. Barriers to Treatment & Access Issues (21:37 - 25:00) 9. Future Directions & Emerging Therapies (25:00 - 28:23) 10. Final Takeaways (28:23 - 29:44) Learning Objectives At the end of this activity, the learner should be better able to: Describe current recommendations for LDL-C screening Identify patients at increased cardiovascular disease risk based on LDL-C levels Describe indications for initiation of statin and nonstatin therapies Identify barriers to therapy initiation and options for resolution Devise evidence-based strategies for optimal lipid management in primary prevention populations Launch Date: 3/31/2025 Expiration Date: 3/30/2026 Joint Accreditation In support of improving patient care, this activity has been planned and implemented by Boston University Chobanian & Avedisian School of Medicine and Vasculearn Network. Boston University Chobanian & Avedisian School of Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Physician CME Hours Boston University Chobanian & Avedisian School of Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Nursing Contact Hours: 0.5, all of which are eligible for pharmacology credits. Pharmacist Contact Hours This activity is approved for 0.5 CPE credit(s) under the ACPE universal activity number JA0000185-9999-25-024-H01-P. The activity is available for credit claiming through March 30, 2026. Speakers Disclosures Dr. Heather Johnson, MD, MS Course Director Disclosures: Dr. Johnson is a consultant for Amgen, Medtronic and Novartis. She is a consultant and a speaker for Esperion. Viet Le, DMSc, MPAS, PA-C Podcast Speaker Disclosures: Dr. Le is on the advisory board for Amarin, Amgen, Bayer, Idorsia, Lexicon, Merck, Novartis and Pfizer. He also receives grant research support from Johnson & Johnson and Janssen, Kardi and AliveCor and Novartis. Off-Label Discussion: will not be included. Accreditor Disclosures The following planning committee members from Boston University Chobanian & Avedisian School of Medicine’s Office of Continuing Medical Education have no relevant financial relationships with ineligible companies: Michael Burk, BS – Operations Manager; Deborah Whalen, APRN, MS, MBA - CNE Accreditation Reviewer. John Fanikos, Rph, MBA Pharmacy Advisor Disclosures: Dr. Fanikos is a consultant for Anthos Therapeutics. He is also a speaker and consultant for AstraZeneca and Pfizer. Boston University Chobanian & Avedisian School of Medicine Disclosure Policy Boston University Chobanian & Avedisian School of Medicine asks all individuals involved in the development and presentation of Accredited Continuing Education activities to disclose all financial relationships with ineligible companies. This information is disclosed to all activity participants prior to ...
    Show More Show Less
    30 mins
  • How Do We Get There from Here: Partnering with Patients to Achieve LDL Goals

    How Do We Get There from Here: Partnering with Patients to Achieve LDL Goals
    Mar 8 2023

    In this episode of Cholesterol Conversations, Drs. Marc Bonaca, Pam Taub, and Heather Johnson discuss how multiagent therapy can improve the provision of care in the real world. Covered topics include new data from the 2023 ACC Scientific Sessions on the efficacy of novel agents and the role of combination therapy, as well as the importance of shared decision-making and keys to managing high-risk populations.
    Show More Show Less
    19 mins
  • ASCVD Management: Making the Case for Nonstatin Therapies

    ASCVD Management: Making the Case for Nonstatin Therapies
    Feb 21 2023

    In this episode of Cholesterol Conversations, join Drs. Neha Pagidipati, Christie Ballantyne, and Gregory Piazza for a roundtable discussion that addresses recent guidance on ASCVD management, current gaps in ASCVD care, patient barriers to LDL-C lowering, and nonstatin therapies to consider for patients who don’t respond to statin therapy alone.
    Show More Show Less
    21 mins

What listeners say about Cholesterol Conversations

Average Customer Ratings

Reviews - Please select the tabs below to change the source of reviews.

Audible.com.au reviews

Amazon Reviews
No Reviews are Available
In the spirit of reconciliation, Audible acknowledges the Traditional Custodians of country throughout Australia and their connections to land, sea and community. We pay our respect to their elders past and present and extend that respect to all Aboriginal and Torres Strait Islander peoples today.